From Financial Post · GlobeNewswire · · 1m 20s
Precede Biosciences Shares ESMO 2026 Data on Prostate Cancer Therapy Response
Precede Biosciences reveals molecular states linked to PSMA therapy success and resistance in advanced prostate cancer.
In brief
Precede Biosciences reveals molecular states linked to PSMA therapy success and resistance in advanced prostate cancer. Precede Biosciences' plasma profiling shows three molecular states predicting response to PSMA therapy in advanced prostate cancer. Originally reported by Financial Post.
Study Finds Three Molecular States
Baseline plasma profiling identified three molecular states previously characterized in tissue: androgen receptor (AR)-high/metabolic, stem/epithelial-mesenchymal transition (EMT), and AR-low/proliferative.
AR-High Group Shows Best Outcomes
The AR-high/metabolic group showed the most favorable outcome trends among the three molecular states.
Gene Set Analysis Confirms Patterns
Analysis of published gene sets corroborated findings: higher stem-like and WNT signaling activity linked to shorter time to next treatment.
AR Signaling Linked to Longer Treatment
Higher AR signaling and luminal A activity associated with longer time to next treatment in metastatic castration-resistant prostate cancer.
PSMA Expression Declines at Progression
At progression, plasma-predicted expression of therapeutic targets including PSMA declined in 11 of 17 patients.
Company Presents ESMO 2026 Data
Precede Biosciences announced new data being presented at ESMO 2026 Congress in Madrid, Spain from October 23-27, 2026.
Treatment Sequencing Strategies
The findings support investigation of treatment-sequencing strategies involving alternative PSMA-targeting modalities and therapies directed at other targets.
The bottom line
Precede Biosciences' plasma profiling shows three molecular states predicting response to PSMA therapy in advanced prostate cancer.
